在小鼠中改善DSS诱导的大肠炎,通过调节微生物代谢和向肠道微生物群
Mengzhen Han1, Jingjing Liang1, Mengxin Hou1
1College of Food Science and Engineering, Northwest A&F University, 712100 Yangling, Shaanxi, China.
Journal of agricultural and food chemistry
|June 5, 2024
概括
双菌 (Bifidobacterium bifidum M1-3) 通过减少炎症和改善肠道屏障功能,有效治疗小鼠结肠炎. 它的治疗作用与肠道微生物群组成和新陈代谢的有益变化有关.
科学领域:
- 胃肠病学 胃肠病学
- 微生物学 微生物学
- 免疫学 免疫学 免疫学
背景情况:
- 炎症性肠病 (IBD) 由于不理想的治疗方法,带来了重大的临床挑战.
- 益生菌显示出治疗大肠炎的潜力,观察到菌株特定的抗炎作用.
研究的目的:
- 为了比较5种Bifidobacterium bifidum菌株的治疗疗效,在硫酸盐 (DSS) 诱导的大肠炎的小鼠模型中.
- 阐明抗炎作用背后的机制,重点关注肠道微生物群和代谢变化.
主要方法:
- 在小鼠中使用DSS诱导大肠炎,然后用不同的B. bifidum菌株进行治疗.
- 评估大肠炎的严重程度,肠道屏障的完整性和结肠炎症.
- 分析肠道微生物群的组成和非向的代谢学.
主要成果:
- 与其他菌株相比,B. bifidum M1-3在改善结肠炎症状,肠道屏障破坏和结肠炎症方面表现出更好的疗效.
- M1-3治疗调节了肠道微生物群,增加了有益的细菌 (例如,Muribaculaceae,Lactobacillus,Bacteroides) 并减少了有害的细菌 (例如,Escherichia-Shigella).
- 代谢分析揭示了M1-3对氨酸代谢,氨酸降解和氨酸代谢等途径的影响,证实了其对肠道微生物群的依赖.
结论:
- B. bifidum M1-3是治疗大肠炎的有希望的益生菌候选者.
- B. bifidum M1-3的治疗效益是通过调节肠道微生物群及其代谢输出来调节的.
- 进一步开发B. bifidum M1-3作为治疗大肠炎的益生菌是有必要的.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Drugs for Treatment of Diarrhea-Predominant IBS
159
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
159
Drugs for Treatment of Ulcerative Colitis in IBD
135
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
135
Chronic Bowel Disorders: Introduction
440
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
440
Inflammatory Bowel Disease IV: Pharmacological Management
126
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
126


